Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer. Read more about Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer.
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. Read more about Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Read more about External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Read more about Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Read more about Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Read more about Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. Read more about Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node. Read more about When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer. Read more about Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Read more about Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
